Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy?

Key Points The molecule, the active ingredient in both Wegovy and Ozempic, powered the company to unprecedented success. With that, however, investor expectations are high, and it's not hard for those folks to be disappointed. 10 stocks we like better than Novo Nordisk › Every pharmaceutical company dreams of having a pioneering blockbuster drug, i.e., one whose annual sales top $1 billion. But that's not a ticket to permanent, automatic success; case in point: Novo Nordisk (NYSE:NVO) . The company rose to fame (after years of relative obscurity) with the semaglutide GLP-1 molecule in the twin blockbusters Ozempic and Wegovy. Over the past few years, however, the semaglutide siblings have come under competitive fire from numerous directions.